SCHEMBL17985355

SCHEMBL17985355

N#Cc1cc2c(nc1Cl)CCNC2

nearest known ligand 0.62

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.62
KDM4E B2RXH2 2/20 0.44
GAA P10253 1/20 0.44
PKM P14618 1/20 0.43
POLB P06746 1/20 0.42
PNMT P11086 4/20 0.41
DRD2 P14416 2/20 0.41
DRD3 P35462 2/20 0.41
CYP3A4 P08684 1/20 0.41
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
ALDH1A1 P00352 1/20 0.39
KHK P50053 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10272300 0.78 CYP3A4 (0.39) SMN1; SMN2KDM4EPOLBPNMTDRD2
SCHEMBL16019318 0.77 SMN1; SMN2 (0.93) SMN1; SMN2KDM4EGAAPKMALDH1A1
SCHEMBL5624979 0.77 SMN1; SMN2 (1.00) SMN1; SMN2KDM4EGAAALDH1A1
SCHEMBL29618412 0.77 SMN1; SMN2 (1.00) SMN1; SMN2KDM4EGAAALDH1A1
SCHEMBL29375167 0.77 SMN1; SMN2 (0.93) SMN1; SMN2KDM4EGAAPKMALDH1A1
SCHEMBL24602713 0.76 CYP3A4 (0.44) SMN1; SMN2POLBPNMTCYP3A4HTR2A
SCHEMBL14635622 0.76 CYP3A4 (0.44) SMN1; SMN2POLBPNMTCYP3A4HTR2A
SCHEMBL7913275 0.76 SMN1; SMN2 (0.97) SMN1; SMN2KDM4EGAAALDH1A1
SCHEMBL30711985 0.73 SMN1; SMN2 (0.64) SMN1; SMN2KDM4EGAAPKMPOLB
SCHEMBL845573 0.73 SMN1; SMN2 (0.64) SMN1; SMN2KDM4EGAAPKMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107207532-B Nitroimidazole derivatives against tuberculosis 南京明德新药研发股份有限公司 2019-07-30 CN disclosed
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative MEDSHINE DISCOVERY INC. (CN) 2019-03-12 US disclosed
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative MEDSHINE DISCOVERY INC. (CN) 2019-03-12 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed
EP-3252059-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE Medshine Discovery Inc. (CN) 2017-12-06 EP disclosed
EP-3252059-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE Medshine Discovery Inc. (CN) 2017-12-06 EP disclosed
CN-107207532-A Nitroimidazole derivatives against tuberculosis 南京明德新药研发股份有限公司 2017-09-26 CN disclosed
WO-2016119706-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE 南京明德新药研发股份有限公司 2016-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE NDUFV1, NDUFV2, MT-ND4 SMN1; SMN2 4595/4885KDM4E 2871/4885GAA 994/4885
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative NDUFV1, NDUFV2, MT-ND4 SMN1; SMN2 4595/4885KDM4E 2871/4885GAA 994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.